DealerTrack Technologies Inc(NASDAQ:TRAK)provides Web-based software solutions and services to the automotive retail industry in the United States and Canada. It offers digital marketing solutions, which provide Websites, digital advertising, and other digital marketing offerings to assist dealers in achieving higher lead conversion rates that assist to optimize various shoppers to their Websites; dealer administration solutions, which provide dealer administration system featuring tools and real-time data access; and F&I solutions that allow dealers to streamline the in-store and online sales, in addition to financing processes.
DealerTrack Technologies Inc(NASDAQ:TRAK) started its trading session with the price of $ 62.85 and closed at $ 62.71 by scoring -0.14% and traded with total volume of 1.81M shares, During last trade its minimum price was $ 62.71 and it gained the highest price of $ 62.95. Its market capitalization was $ 3.44B.
Geron Corporation(NASDAQ:GERN) a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has partnership and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, counting hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
Geron Corporation(NASDAQ:GERN) showing jumped of 0.49 % and closed at $4.08, after gaining total volume of 2.03M shares. Its opening price was $4.08. Its earnings per share(EPS) is $-0.23 and its beta value stands at 2.16 points and has total market capitalization of $641.84M and a total of 158.09M outstanding shares.
Biomed Realty Trust Inc(NYSE:BMR)declared that its board of directors has declared a second quarter 2015 dividend of $0.26 per share of common stock. The dividend is equivalent to an annualized dividend of $1.04 per common share.
The common stock dividend is payable on July 15, 2015 to stockholders of record at the close of business on June 30, 2015.
Biomed Realty Trust Inc(NYSE:BMR) reported the plunge of -0.61 % and closed at $19.56, with the total traded volume of 1.44M shares and opening price was $19.65. During last trade its minimum price was $19.54 and it gained its highest price of $19.76 and has a total of 203.56M outstanding shares and its total market capitalization is $4.01B.
Transition Therapeutics Inc (USA)(NASDAQ:TTHI) declared that a Phase 2/3 clinical study of neuropsychiatric drug candidate ELND005 did not meet its primary efficacy endpoint. In the study, both the treatment and placebo groups showed a significant, but similar, reduction in agitation and aggression relative to baseline. There was a greater than predictable reduction in agitation and aggression observed in the placebo group as measured in weeks 4, 8 and 12 in the study. The safety and tolerability profile of ELND005 comprised with previous studies in AD at the 250mg bid dose.
The Phase 2/3 clinical study evaluated the efficacy, safety and tolerability of ELND005 over 12 weeks of treatment in patients with mild to severe AD, who were experiencing at least moderate levels of agitation/aggression. The randomized, double-blind, placebo-controlled study enrolled 350 AD patients (175 subjects per study arm). The primary efficacy endpoint of the study was the change from baseline in the Neuropsychiatric Inventory – Clinician (“NPI-C”) scale of agitation and aggression.
Transition Therapeutics Inc (USA)(NASDAQ:TTHI) reported the surge of 7.66 %, after closing price for the day was $2.53 and opening at the price of $2.70. Its total trading volume for the day was 172,312.00 shares, Its earnings per share are $ -1.22.